Adaptimmune Therapeutics PLC
ADAP0.055USD
0.000
Close 12/19, 16:00（ET）Quotes delayed by 15 min
87.31MMarket Cap
LossP/E TTM
More Details of Adaptimmune Therapeutics PLC Company
Adaptimmune Therapeutics PLC is focused on pre-clinical programs, including PRAME and CD70-directed T-cell therapies, and its allogeneic pipeline. PRAME is highly expressed across a range of solid tumors, including ovarian, endometrial, lung and breast cancers. The CD70 program targets the CD70 antigen, which is expressed across a range of hematological malignancies (acute myeloid leukemia and lymphoma) and solid tumors (renal cell carcinoma). It is using TRuC technology to develop a T-cell therapy (ADP-520) against CD70, with membrane bound IL-15 to enhance persistence. ADP-520 is in pre-clinical testing. TRuC technology combines the targeting of CAR-T cells with T-cell TCR signaling.
Adaptimmune Therapeutics PLC Info
Ticker SymbolADAP
Company nameAdaptimmune Therapeutics PLC
IPO dateMay 06, 2015
CEORawcliffe (Adrian George)
Number of employees506
Security typeDepository Receipt
Fiscal year-endMay 06
Address60 Jubilee Avenue
CityABINGDON
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited Kingdom
Postal codeOX14 4RX
Phone441235430000
Websitehttps://www.adaptimmune.com/
Ticker SymbolADAP
IPO dateMay 06, 2015
CEORawcliffe (Adrian George)
Company Executives of Adaptimmune Therapeutics PLC
Name
Name/Position
Position
Shareholding
Change
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
611.22K
+191.15%
Mr. Lawrence M. (Larry) Alleva, CPA
Mr. Lawrence M. (Larry) Alleva, CPA
Non-Executive Independent Director
Non-Executive Independent Director
23.89K
--
Mr. Christopher Hill
Mr. Christopher Hill
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Adrian Rawcliffe
Mr. Adrian Rawcliffe
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. William C. (Bill) Bertrand, Jr., Esq.
Mr. William C. (Bill) Bertrand, Jr., Esq.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. John P. Furey
Mr. John P. Furey
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Andrew Allen, M.D., Ph.D.
Dr. Andrew Allen, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Kristen M. Hege, M.D.
Dr. Kristen M. Hege, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
611.22K
+191.15%
Mr. Lawrence M. (Larry) Alleva, CPA
Mr. Lawrence M. (Larry) Alleva, CPA
Non-Executive Independent Director
Non-Executive Independent Director
23.89K
--
Mr. Christopher Hill
Mr. Christopher Hill
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Adrian Rawcliffe
Mr. Adrian Rawcliffe
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. William C. (Bill) Bertrand, Jr., Esq.
Mr. William C. (Bill) Bertrand, Jr., Esq.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. John P. Furey
Mr. John P. Furey
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Long Focus Capital Management LLC
7.01%
UBS Financial Services, Inc.
2.47%
Renaissance Technologies LLC
1.53%
Morgan Stanley & Co. LLC
1.38%
Jane Street Capital, L.L.C.
1.06%
Other
86.56%
Shareholders
Shareholders
Proportion
Long Focus Capital Management LLC
7.01%
UBS Financial Services, Inc.
2.47%
Renaissance Technologies LLC
1.53%
Morgan Stanley & Co. LLC
1.38%
Jane Street Capital, L.L.C.
1.06%
Other
86.56%
Shareholder Types
Shareholders
Proportion
Hedge Fund
8.54%
Investment Advisor
3.42%
Research Firm
2.99%
Investment Advisor/Hedge Fund
0.84%
Individual Investor
0.63%
Pension Fund
0.07%
Bank and Trust
0.05%
Venture Capital
0.04%
Other
83.43%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
165
42.25M
57.79%
-8.12K
2025Q3
183
42.26M
58.51%
-57.25M
2025Q2
189
116.07M
65.05%
-1.37M
2025Q1
186
117.46M
62.78%
-44.42M
2024Q4
186
127.90M
58.86%
-11.67M
2024Q3
189
154.60M
64.35%
-2.20M
2024Q2
192
156.54M
67.34%
-7.97M
2024Q1
203
164.83M
67.18%
-6.80M
2023Q4
199
145.59M
71.95%
-5.54M
2023Q3
217
150.77M
70.44%
+3.59M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Long Focus Capital Management LLC
23.76M
8.96%
--
--
Jun 30, 2025
Renaissance Technologies LLC
1.88M
0.71%
+69.00K
+3.80%
Jun 30, 2025
Morgan Stanley & Co. LLC
4.22M
1.59%
+1.59M
+60.49%
Jun 30, 2025
Acadian Asset Management LLC
1.96M
0.74%
-254.07K
-11.45%
Jun 30, 2025
BofA Global Research (US)
1.14M
0.43%
-5.30K
-0.46%
Jun 30, 2025
Alpha Architect, LLC
800.00K
0.3%
+800.00K
--
Jun 30, 2025
Menzel (Garry E)
611.22K
0.23%
+401.29K
+191.15%
Apr 11, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ActivePassive International Equity ETF
0%
Fidelity Enhanced Small Cap ETF
0%
SPDR S&P International Small Cap ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
SPDR Portfolio Developed World ex-US ETF
0%
ActivePassive International Equity ETF
Proportion0%
Fidelity Enhanced Small Cap ETF
Proportion0%
SPDR S&P International Small Cap ETF
Proportion0%
Invesco NASDAQ Future Gen 200 ETF
Proportion0%
SPDR Portfolio Developed World ex-US ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Adaptimmune Therapeutics PLC?
The top five shareholders of Adaptimmune Therapeutics PLC are:
Long Focus Capital Management LLC holds 23.76M shares, accounting for 8.96% of the total shares.
Renaissance Technologies LLC holds 1.88M shares, accounting for 0.71% of the total shares.
Morgan Stanley & Co. LLC holds 4.22M shares, accounting for 1.59% of the total shares.
Acadian Asset Management LLC holds 1.96M shares, accounting for 0.74% of the total shares.
BofA Global Research (US) holds 1.14M shares, accounting for 0.43% of the total shares.
Long Focus Capital Management LLC holds 23.76M shares, accounting for 8.96% of the total shares.
Renaissance Technologies LLC holds 1.88M shares, accounting for 0.71% of the total shares.
Morgan Stanley & Co. LLC holds 4.22M shares, accounting for 1.59% of the total shares.
Acadian Asset Management LLC holds 1.96M shares, accounting for 0.74% of the total shares.
BofA Global Research (US) holds 1.14M shares, accounting for 0.43% of the total shares.
What are the top three shareholder types of Adaptimmune Therapeutics PLC?
The top three shareholder types of Adaptimmune Therapeutics PLC are:
Long Focus Capital Management LLC
UBS Financial Services, Inc.
Renaissance Technologies LLC
Long Focus Capital Management LLC
UBS Financial Services, Inc.
Renaissance Technologies LLC
How many institutions hold shares of Adaptimmune Therapeutics PLC (ADAP)?
As of 2025Q4, 165 institutions hold shares of Adaptimmune Therapeutics PLC, with a combined market value of approximately 42.25M, accounting for 57.79% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.72%.
What is the biggest source of revenue for Adaptimmune Therapeutics PLC?
In --, the -- business generated the highest revenue for Adaptimmune Therapeutics PLC, amounting to -- and accounting for --% of total revenue.
